About: Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.97 (+0.34%)
EVAX NASDAQ Evaxion Biotech AS
Evaxion Biotech AS share price
EVAX price activity
Last Price
$2.970
Change (24hr)
0.01 USD (0.34%)
Volume
27.62K
Volume (4w avg)
-
Open
$3.05
Day Range
$2.97 - $3.16
Previous Close
$2.96
Last Trade
04 Nov, 9:00 pm GMT+0
Delayed
04 Nov, 9:00 pm GMT+0
EVAX price performance
Delayed
04 Nov, 9:00 pm GMT+0
EVAX details
EVAX Market Signals